ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Clinical Toxicology, the American Academy of Emergency Medicine, and the American College of Emergency Physicians is as follows: To increase access for patients to receive treatment for opioid use...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medical toxicology 2019-10, Vol.15 (4), p.307-309
Hauptverfasser: Marino, Ryan, Perrone, Jeanmarie, Nelson, Lewis S., Wiegand, Timothy J., Schwarz, Evan S., Wax, Paul M., Stolbach, Andrew I.
Format: Artikel
Sprache:eng
Schlagworte:
Biomedical and Life Sciences
Biomedicine
Buprenorphine
Drug addiction
Drug overdose
Emergency medical care
Emergency medical services
FDA approval
Medicine
Methadone
Narcotics
Opioids
Pain
Pharmacology/Toxicology
Physicians
Position Statement
Primary care
Public health
Toxicology
Waivers
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Clinical Toxicology, the American Academy of Emergency Medicine, and the American College of Emergency Physicians is as follows: To increase access for patients to receive treatment for opioid use disorder in the United States, we strongly recommend removing the waiver (“Xwaiver”) requirement for buprenorphine prescribing
ISSN:1556-9039
1937-6995
DOI:10.1007/s13181-019-00728-9